Evidence map›Paper›PMID 34675049›Full record

ArticleThe European respiratory journal2022

Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?

Emily M Hartsell, Mark N Gillespie, Raymond J Langley

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. ORF8/ORF8a: a difference between SARS-CoV-2 and SARS-CoV.The European respiratory journal · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Emily M HartsellDept of Pharmacology, University of South Alabama College of Medicine, Mobile, AL, USA.
Mark N GillespieDept of Pharmacology, University of South Alabama College of Medicine, Mobile, AL, USA.
Raymond J LangleyDept of Pharmacology, University of South Alabama College of Medicine, Mobile, AL, USA rlangley@southalabama.edu.ORCID 0000-0001-8849-9325

Funding

National Dissemination of I-Corps@NCATS: Accelerating Translation through CommercializationUL1TR003096 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GUTIERREZ, ORLANDO M, KIMBERLY, ROBERT P. · 2019 to 2023
$43.6M
DEEP SOUTH TRANSLATIONAL RESEARCH MENTORED CAREER DEVELOPMENT PROGRAMKL2TR003097 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2019 to 2023
$5.2M
MtDNA repair: An isolated pharmacologic target in acute lung injuryR01HL113614 · NHLBI · UNIVERSITY OF SOUTH ALABAMA · PI GILLESPIE, MARK N · 2012 to 2021
$3.5M
mtDNA damage and DAMPs in multiple organ dysfunction syndromeR01GM127823 · NIGMS · UNIVERSITY OF SOUTH ALABAMA · PI GILLESPIE, MARK N · 2019 to 2022
$1.8M
Metabolic Energy Crisis Signature Predicts Quality of Life in Survivors of Acute Respiratory FailureR21NR019338 · NINR · UNIVERSITY OF SOUTH ALABAMA · PI LANGLEY, RAYMOND JULIAN · 2021 to 2022
$450k
NCATS NIH HHS KL2 TR003097NCATS NIH HHS UL1 TR003096NHLBI NIH HHS R01 HL113614NIGMS NIH HHS R01 GM127823NINR NIH HHS R21 NR019338
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Graft vs Host DiseaseBiomarkersHumansSARS-CoV-2Biomarkers

Identifiers

PMID34675049
PMCPMC8542864

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.